News
The FDA has accepted for Priority Review the New Drug Application for TransCon CNP (navepegritide) for the treatment of children with achondroplasia.
Simplified method using left atrial volume and natriuretic peptides streamlines diagnosis of heart failure with preserved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback